Thyme Care Secures $97M Series D Funding, Achieves Unicorn Status in Cancer Care Navigation

Thyme Care, a value-based cancer care navigation company, has raised $97 million in a Series D funding round, propelling its valuation to over $1 billion. The investment, backed by major strategic players across the healthcare spectrum, marks a significant milestone for the company and underscores the growing importance of innovative approaches to cancer care management.

Strategic Investors and Expansion Plans

The latest funding round attracted a diverse group of investors, including CVS Health Ventures, Humana, Morgan Health, and Memorial Hermann Health System. Existing investors such as Foresite Capital, a16z Bio + Health, and Frist Cressey Ventures also participated, demonstrating continued confidence in Thyme Care's mission.

Robin Shah, CEO and co-founder of Thyme Care, outlined the company's plans to utilize the new capital for expanding across verticals and addressing critical issues in the oncology journey. "We're now focused on tackling treatment denials, high drug costs, and the barriers that delay or prevent access to timely, affordable, and appropriate care," Shah stated.

Technological Advancements and AI Integration

Thyme Care is set to accelerate investments in technology and artificial intelligence to enhance care delivery. The company plans to hire tech leaders to advance its AI platform strategy, with a focus on developing member-facing apps and tech solutions for its care team. This technological push aims to support the company's rapid scaling as it forges new partnerships with national and local health plans.

Impressive Growth and Financial Performance

Since its founding in 2020, Thyme Care has experienced remarkable growth. The company now manages 80,000 actively treated cancer patients, a significant increase from 10,000 at the end of 2024. Thyme Care has achieved profitability and currently manages more than $5 billion in oncology spend.

The company's partnerships have expanded to include major payers such as Aetna and Humana, Fortune 500 employers, and leading health systems. Thyme Care's services are now accessible to 8 million people, reflecting its successful scaling strategy and the growing demand for its innovative approach to cancer care navigation.